NORTHWEST BIOTHERAPEUTICS Aktie

0,18 EUR 0,0000%

Zu Ihrem Onlinebroker

kaufen verkaufen

NORTHWEST BIOTHERAPEUTICS Aktienkurs : 25.05. ( 15 Min. verzögert)
0,180 € Letzter Kurs	0,00% Veränderung	0,180 € Vortag	0,180 € Eröffnungskurs

Realtime:

0,18

0,00%

mehr Informationen

Hoch/Tief		Volumen		Geldkurs	Briefkurs
0,180 - 0,180 Tag	0,700 - 0,140 52 Wochen	0 Tag	40 Ø 52 Wochen	0,0000000 0 Stücke	0,0000000 0 Stücke

NORTHWEST BIOTHERAPEUTICS Akt…

Wollen Sie wissen, wie es mit dieser Aktie weitergeht?
Wir informieren Sie kostenlos.

Erhalten Sie außerdem Expertenanalysen von:
Gevestor Täglich und John Gossens Daily DAX

25.05.

Gaithersburg drug-maker signs deal for European market

Northwest Biotherapeutics reported that the 41-center study of its brain cancer vaccine has been designated a phase 3 trial by the Food and Drug Administration. The FDA also OK'd an expansion of …
23.05.

Darling Dendreon Takes Hits As Speculators Continue To Bet On Immunotherapy Plays

OB) and Northwest Biotherapeutics (NWBO.OB) have gone out of their way to let investors know that they plan to employ less taxing manufacturing processes,...

22.05.

As Darling Dendreon Takes Hits Others Continue To Thrive

Other emerging cancer-immunotherapy companies in Phase II like glioblastoma treatment rivals ImmunoCellular Therapeutics (OTCBB:IMUC) and Northwest Biotherapeutics (OTCBB:NWBO) have gone out of their way to let investors know that they plan to employ ...
21.05.

Brain Cancer Trial - Northwest Update on DCVAX®

BETHESDA, MD, May 17, 2012 — Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) announced today that it now has 41 clinical trial sites open and recruiting across the United...
17.05.

Smart Biotech Management For Clinical Trial Paths

Celgene last traded at 70.72 with a 52 week range of 51.70 - 80.42 and a market cap. of 31.15B. Northwest Biotherapeutics (NWBO.OB) is a developmental stage biotech company focused on immunotherapies that use a patient's own cells to produce ...